To evaluate the effectiveness and safety of sirolimus therapy in a child with macroglossia due to lymphatic malformation.
Methods:
Sirolimus treatment was applied to the patient with an initial dosing of 0.8 mg/m2 per dose, administered orally, twice daily at approximately 12-hour intervals.
Results:
After 9 months of sirolimus therapy, there was a nearly complete resolution of lymphatic malformation. The last evaluation was performed 6 months after withdrawal of treatment, and the lesion had almost completely resolved.
Conclusion:
This article presents a novel approach to the treatment of lymphatic malformation of the tongue using sirolimus, which appears to be safe and effective for the management of complex cases.
GriessenauerCJBilalMKankirawatanaP. Lymphatic malformation of the tongue with coexisting intractable epilepsy treated with corpus callosotomy: a case report. Clin Neurol Neurosurg. 2014;117:68-70.
2.
StandringS.HG. Section 3. Head and neck posterior triangle. In: Gray’s Anatomy. British ed. London: Churchill Livingstone; 2011:1825-1861.
3.
NitnawareAZSakharePTKapreGM. Cystic hygroma with extensive tongue involvement. Indian J Otolaryngol Head Neck Surg. 2011;63:89-92.
4.
HammillAMWentzelMSGuptaA. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer. 2011;57:1018-1024.
5.
ThottamPJAl-BaraziRMadgyDNRozellaA. Submucosal resection of a microcystic oropharyngeal lymphatic malformation using radiofrequency ablation. Int J Pediatr Otorhinolaryngol. 2013;77:1589-1592.
6.
AzizkhanRGRutterMJCottonRT. Lymphatic malformations of the tongue base. J Pediatr Surg. 2006;41:1279-1284.
7.
BrennanTDMillerASChenSY. Lymphangiomas of the oral cavity: a clinicopathologic, immunohistochemical, and electron-microscopic study. J Oral Maxillofac Surg. 1997;55:932-935.
8.
FageehNManoukianJTewfikT. Management of head and neck lymphatic malformation in children. J Otolaryngol. 1997;26:253-258.
9.
GallagherPGMahoneyMJGoscheJR. Cystic hygroma in the fetus and newborn. Semin Perinatol. 1999;23:341-356.
10.
BoardmanSJCochraneLARoebuckD. Multimodality treatment of pediatric lymphatic malformations of the head and neck using surgery and sclerotherapy. Arch Otolaryngol Head Neck Surg. 2010;136:270-276.
11.
GoswamiMSinghSGokkulakrishnanSSinghA. Lymphangioma of the tongue. Natl J Maxillofac Surg. 2011;2:86-88.
FliegelmanLJFriedlandDBrandweinMRothschildM. Lymphatic malformation: predictive factors for recurrence. Arch Otolaryngol Head Neck Surg. 2000;123:706-710.
14.
MarxRESternD. Oral and Maxillofacial Pathology: A Rationale for Diagnosis and Treatment. Carol Stream, IL: Quintessence Publishing Co, Inc; 2003:435-437.
15.
KarmadyCSFortsonJKCalcaterraVE. Lymphangiomas of the head and neck in adults. Otolaryngol Head Neck Surg. 1982;90:283-288.
16.
VignotSFaivreSAguirreD. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol. 2005;16:525-537.
17.
GubaMvonBPSteinbauerM. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8:128-135.
18.
PerryBBanyardJMcLaughlinER. AKT1 overexpression in endothelial cells leads to development of cutaneous vascular malformations in vivo. Arch Dermatol. 2007;143:504-506.
19.
ReinglasJRamphalRBromwichM. The successful management of diffuse lymphangiomatosis using sirolimus: a case report. Laryngoscope. 2011;121:1851-1854.
20.
AkyüzCAtaşEVaranA. Treatment of a tongue lymhangioma with sirolimus after failure of surgical resection and propranolol. Pediatr Blood Cancer. 2014;61:931-932.
